Clinical trials: Pneumopathy
Carcinoma, Non-Small-Cell Lung
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
It has been accepted and proven that patients with unresectable lung cancer can benefit from systemic chemotherapy. Traditional platinum-based therapy has significant side effects.
- Trial name
- NCT00145418
- Testing
- Oxaliplatin + Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oncology Specialists, S.C.
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.
- Trial name
- NCT02343458
- Testing
- GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001)
- Where
- 166 sites in United States, China and 9 more
- Volunteers
- 1,756 people
- Sponsor
- Pearl Therapeutics, Inc.
Allergic Asthma
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis.
- Trial name
- X-PAND (NCT00813748)
- Testing
- Xolair
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Carcinoma, Non-Small-Cell Lung
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
The LUME-Lung3 study is in 2 parts: Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.
- Trial name
- NCT01346540
- Testing
- BIBF 1120
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Nonsmall Cell
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body Positron Emission Tomography/Computerized Tomography scanner to obtain…
- Trial name
- NCT04678440
- Testing
- [18F]F-AraG Imaging
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
SARS-CoV2 Infection
Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
10 asymptomatic DHCWs in the Oral Medicine clinic, Rutgers School of Dental Medicine, with no history of documented COVID-19 infection or viral exposure, were enrolled in a study that interrogated DHCWs' perceptions of safety and…
- Trial name
- PREDICT-DHCW (NCT05607147)
- Testing
- Testing for SARS CoV2 Antigen and Antibody
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
- Trial name
- NCT01313676
- Testing
- fluticasone furoate/vilanterol, fluticasone furoate, vilanterol
- Where
- 1,611 sites in United States, Argentina and 42 more
- Volunteers
- 16,568 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
The aim of the study is to compare the efficacy of roflumilast to placebo on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of…
- Trial name
- HELIOS (NCT00424268)
- Testing
- Roflumilast
- Where
- 103 sites in Austria, France and 5 more
- Volunteers
- 743 people
- Sponsor
- AstraZeneca
Asthma, COPD
Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma
The purpose of the study is to better understand proteomics of asthma and COPD, and response to therapy. There are two Phases to this study broken into two arms.
- Trial name
- Proteomics (NCT02487394)
- Testing
- Exhaled Breath Condensate (EBC)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Asthma
A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
The primary objective of this study is to determine the efficacy and safety of 4 doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily for four weeks in patients with asthma in comparison to…
- Trial name
- NCT01013753
- Testing
- Olodaterol (BI 1744) high, Olodaterol (BI 1744) medium, Olodaterol (BI 1744) very low
- Where
- 27 sites in Austria, Germany and 4 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Asthma, Lung Diseases
Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)
The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on…
- Trial name
- CAMP (NCT00000575)
- Testing
- Nedocromil, Budesonide
- Volunteers
- 1,041 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
COPD
Peak Inspiratory Flow Rates in Patients With COPD
Recent studies have reported that some Chronic Obstructive Pulmonary Disease (COPD) patients may have a suboptimal ability to generate a sufficient inspiratory effort to achieve adequate lung delivery of inhaled medications…
- Trial name
- NCT04168775
- Testing
- Home PIFR monitoring with InCheck Dial
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of North Carolina, Chapel Hill
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
Stage III Non-small Cell Lung Cancer, Unresectable
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents.
- Trial name
- COAST (NCT03822351)
- Testing
- Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 189 people
- Sponsor
- MedImmune LLC
SARS-CoV-2 Infection
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19.
- Trial name
- NCT05799495
- Testing
- PF-07817883
- Where
- 53 sites in United States
- Volunteers
- 240 people
- Sponsor
- Pfizer
Asthma
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma
- Trial name
- DIRECTION (NCT03927157)
- Testing
- Experimental: Tezepelumab
- Where
- 72 sites in China, Philippines and 1 more
- Volunteers
- 405 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.